Showing results (311-320 of 501) with videos related to
Sort By:
Pageof 51
The American Journal of Medicine|August 1, 1986
Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patientsC J Logothetis, M L Samuels, D E Selig, et al.Academic Medicine : Journal of the Association of American Medical Colleges|August 1, 1992
An objective structured clinical examination for the licentiate: report of the pilot project of the Medical Council of CanadaR Reznick, S Smee, A Rothman, et al.Cancer Chemotherapy and Pharmacology|May 18, 2023
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphomaKatelyn N Purvis, Hope D Swanson, Kumar Kulldeep Niloy, et al.Pediatric Blood & Cancer|July 26, 2024
Blinatumomab infusion interruptions in pediatric patients rarely lead to readmissionJonathan Moody, Patricia J Barker, Joseph Sciasci, et al.Oncology Reports|June 19, 2001
Radical cystectomy for invasive bladder cancer in the octogenarianR S Lance, C P Dinney, D Swanson, et al.The Journal of Biological Chemistry|December 6, 2011
Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 ActivationZi Fang, Tao Zhang, Nishtman Dizeyi, et al.Journal of Medicinal Chemistry|April 1, 1987
Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivativesW S Marshall, T Goodson, G J Cullinan, et al.The Journal of Bone and Joint Surgery. American Volume|October 1, 1985
Unicompartmental and bicompartmental arthroplasty of the knee with a finned metal tibial-plateau implantA B Swanson, G D Swanson, T Powers, et al.AIDS Research and Human Retroviruses|May 22, 2012
Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strainsGeoffrey Férir, Dana Huskens, Kenneth E Palmer, et al.The Journal of Pharmacology and Experimental Therapeutics|April 1, 1985
LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonistJ H Fleisch, L E Rinkema, K D Haisch, et al.Pageof 51